ClinicalTrials.Veeva

Menu

A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

Yale University logo

Yale University

Status

Withdrawn

Conditions

Hemangioma

Study type

Observational

Funder types

Other

Identifiers

NCT00974129
Yale-0430
0507000430

Details and patient eligibility

About

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

Full description

This study seeks to examine a potential relationship between CTCF genotype and hemangioma size and growth rate. In addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. At each visit, patients' hemangiomas will be measured and photographed. At one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of C/T polymorphism at CTCF binding site six.

Sex

All

Ages

Under 1 year old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Hemangioma must appear within one month prior to enrollment

Exclusion criteria

  • Hemangioma appeared before one month prior to enrollment

Trial design

0 participants in 1 patient group

Patients with Infantile Hemangiomas

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems